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Abstract 
1,2-Diazetidin-3-ones are readily accessible, small ring scaffolds that upon functionalization 
have the potential to produce diverse 3-dimensional structures for drug discovery. Thus 
treatment of diazo hydrazides, obtained from simple hydrazides and malonyl half ester 
derivatives, followed by diazo transfer, with catalytic amounts of rhodium(II) acetate dimer 
results in intramolecular carbenoid N–H insertion to give 1,2-diazetidin-3-ones. Although 
subsequent functionalization reactions could be hampered by the lability of the 4-membered 
ring, a wide range of new derivatives was available by deprotection at N-1, and subsequent 
amide or urea formation. The structures of four four-membered rings was confirmed by X-ray 
crystallography; the compounds showed modest growth inhibitory activity in mammary 
carcinoma cells. 
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Four-membered rings are increasingly prevalent as bioactive scaffolds in drug discovery 
programmes.[1] Not only do they add structural novelty in under-explored areas of chemical 
space, they can also contribute to enhanced physicochemical properties. This has been 
amply illustrated by the dramatic increase in interest in oxetane ring systems in recent 
years.[2] One four-membered ring that attracted our attention is the 1,2-diazetidin-3-one core 
structure (Figure 1).[3] Although known for almost a 100 years, this small ring system remains 
largely unexplored in medicinal chemistry, but has recently attracted renewed attention 
following the discovery that they act as potent inhibitors of the serine hydrolase protein 
phosphatase methylesterase-1 by acylation of the key serine residue.[4] Notwithstanding their 
potential liability toward ring opening, these densely functionalized small rings possess well-
defined vectors, and form a worthwhile low molecular weight scaffold for drug discovery.  
 
 
Figure 1. The 1,2-diazetidin-3-one scaffold. 
 
To examine the potential molecular and structural diversity of the 1,2-diazetidin-3-one 
scaffold a virtual library was enumerated using LLAMA (Lead-Likeness And Molecular 
Analysis).[5] A virtual library of 177 compounds based on 3 core scaffolds was shown to have 
suitable molecular properties as lead compounds for drug discovery (RMM = 369, ALogP = 
1.11, pTSA = 104 Å2). Additionally, the 1,2-diazetidinone fragment is highly distinctive from 
existing fragment databases. The Murko framework[6] of the 1,2-diazetidinone core was not 
found as a substructure in a random 2% sample of the ZINC database of commercially 
available compounds.[7] Furthermore, examining the molecular shape of the virtual library 
using a PMI plot indicates that diverse three-dimensional molecular shape can be achieved 
by functionalization of the 1,2-diazetidinone core (Figure 2).	
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Figure 2. Principal moments of inertia (PMI) plot of the prepared scaffolds, generated using 
LLAMA.  
 
In addition to being an attractive scaffold for further functionalization, 1.2-diazetidin-3-ones 
are aza-analogues of the well known β-lactam antibiotics. Despite being discovered 90 years 
ago, β-lactam antibiotics continue to play a key role in clinical practice and remain one of the 
best-investigated families of antibiotics. Their mode of action and susceptibility to resistance 
via β-lactamase enzymes have been widely studied, resulting in the chemical synthesis and 
biological evaluation of numerous derivatives and analogues.[8] Much of the interest in 
analogues has focused on the modification of the ring system of naturally occurring β-
lactams such as the penicillins and cephalosporins. Such analogues often incorporate an 
additional nitrogen atom in the ring, and include 2-azapenems,[9] 3-azacephams,[9b] and 1-
azacephems (Figure 3).[10] 1,2-Diazetidin-3-ones represent an alternative aza-β-lactam 
analogue that places the additional nitrogen in the four-membered ring itself.  
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Figure 3. Naturally occurring β-lactams and some aza-analogues. 
 
1,2-Diazetidin-3-ones were originally prepared almost a century ago by Staudinger by 
reaction of azo compounds with ketenes.[11] The process has been subject of renewed 
interest with the development of enantioselective versions using asymmetric nucleophilic 
catalysis (Scheme 1A),[12] although it remains somewhat limited in its substrate scope. In 
contrast, in seminal work Taylor and co-workers described versatile routes to 1,2-diazetidin-
3-ones based on the cyclization of benzophenone chloroacetylhydrazone, followed by 
treatment with 4-toluenesulfonic acid to give the parent ring system for further elaboration 
(Scheme 1B).[13] Our own contributions centered on the intramolecular N–H insertion reaction 
of rhodium carbene intermediates derived from diazocarbonyl compounds (Scheme 1C).[14] 
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Scheme 1. Routes to 1,2-diazetidin-3-ones. 
 
Despite the development of successful synthetic routes,[3] 1,2-diazetidinones remain poorly 
investigated, and attempts to further develop their chemistry have often foundered due to 
their lability and inherent ring strain. We now report a detailed study on the synthesis of a 
range of 1,2-diazetidin-3-one scaffolds using the versatile rhodium carbene methodology, 
followed by their subsequent derivatization reactions, and preliminary biological evaluation. 
 
Results and Discussion 
The synthesis began with the reaction between benzaldehyde and tert-butyl carbazate 
followed by reduction with cyanoborohydride to form the hydrazine 1a. Treatment with methyl 
malonyl chloride and triethylamine in dichloromethane at room temperature gave the desired 
1,3-dicarbonyl compound 2a in 70% yield (Scheme 2). Subsequent diazo group transfer 
reaction using p-acetamidobenzenesulfonyl azide (p-ABSA)[15] in the presence of DBU 
afforded diazocarbonyl compound 3a in good yield. The diazocarbonyl compound represents 
the key substrate for the overall strategy, and treatment with a catalytic amount of rhodium(II) 
acetate dimer (3 mol%) induced metallocarbene formation and intramolecular N–H insertion 
providing the 1,2-diazetidin-3-one 4a as a single product in 79% yield after chromatographic 
purification. The same synthetic sequence was applied to the hydrazine 1b derived from 
furfural, and delivered the 1,2-diazetidin-3-one 4b in comparable fashion. Likewise the 
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corresponding benzyl ester 4c was prepared as outlined in Scheme 2. As expected, the 1,2-
diazetidin-3-ones exhibited a high frequency carbonyl stretch at ca. 1800 cm-1 in their IR 
spectra. 
 
 
Scheme 2. Synthesis of 1-Boc-1,2-diazetidinones, and their deprotection and re-acylation.  
 
With the 4-membered heterocycle in hand, it was a priority to establish its ability to participate 
in a range of functionalization reactions. Initial attempts to remove the Boc-protecting group 
under standard acidic conditions were unsatisfactory, but exposure of aza-β-lactams 4a and 
4b to boron trifluoride etherate[16] resulted in clean removal of the nitrogen protecting group to 
deliver the 1,2-diazetidin-3-ones 5 in which N-1 is free for further elaboration. Exemplar 
acylation reactions at N-1 using acetyl chloride proceeded smoothly to provide derivatives 6 
(Scheme 2).  
 
In parallel, and in order to expand the structural variation in the 1,2-diazetidinones through 
functional group interconversion, we attempted to hydrolyze the 4-carboxylate ester in 1,2-
diazetidinone 4a to the corresponding carboxylic acid 7. Standard alkaline hydrolysis 
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conditions resulted in rapid consumption of ester 4a, but no carboxylic acid 7 could be 
isolated. Likewise use of Me3SiOK or Me3SnOH as reagents was unsuccessful. In all cases, 
a complex mixture of products was observed, suggesting that the 1,2-diazetidin-3-one ring is 
unstable under such conditions. Therefore, we switched our attention to the corresponding 
benzyl ester 4c in the expectation that it could be cleaved under non-nucleophilic conditions 
by hydrogenolysis. In the event, this was the case, and the carboxylic acid 7 could be 
isolated in 65% yield after hydrogenolysis over palladium on charcoal (Scheme 3). However, 
the acid 7 proved to be unstable, and decomposed within a few hours of its preparation. 1H 
and 13C NMR spectroscopic analysis of the resulting degradation products did not provide 
evidence for decomposition by a simple process such as decarboxylation. Nevertheless a 
range of amide coupling reactions was investigated using benzylamine as a model amine 
nucleophile. The first amide coupling agent evaluated was HATU which enabled the 
formation of amide 8, the structure of which was confirmed by X-ray crystallography, in poor 
yield of 21%. Use of EDCI, CDI or PyBOP® was unsuccessful, whereas other coupling 
agents such as 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride 
(DMTMM), prepared in situ from 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) and N-
methylmorpholine (NMM), and propylphosphonic anhydride (T3P) resulted in similar yields 
for amide 8. Direct amidation attempts using the trimethylaluminum reagent, DABAL-Me3[17] 
also gave disappointing results. Presumably the low yields in amide coupling reactions again 
reflect the instability of 1,2-diazetidinone-4-carboxylic acid. 
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Scheme 3. Formation of 1,2-diazetidinone-4-carboxylic acid, and amide formation; X-ray 
crystal structure of amide 8 (CCDC 1829702).  
 
Given the instability of the 1,2-diazetidinone-4-carboxylic acid, and the resulting poor yields in 
amide formation, we investigated the alternative strategy in which the amide is formed before 
the construction of the 4-membered ring. Thus hydrazine derivatives 2b, 2d and 2e (Scheme 
2) were hydrolyzed to the corresponding acids in near quantitative yields, and coupled to 
morpholine as a representative amine to give the amides 9 (Scheme 4). Diazo transfer 
proceeded smoothly using o-nitrobenzenesulfonyl azide (o-NBSA),[18] the original conditions 
employing p-ABSA being unsatisfactory. The resulting diazocarbonyl compounds 10 
underwent rhodium(II) catalyzed N–H insertion to give the 1,2-diazetidin-3-ones 11. As 
before, treatment with boron trifluoride etherate successfully removed the N-1 protecting 
group in good to excellent yield, and the resulting amine 12 underwent amide coupling with a 
range of representative acid chlorides to give amides 13a-f (Scheme 4). The structures of 
amides 13a, 13b and 13d were confirmed by X-ray crystallography (Figure 4). In a similar 
manner, 1,2-diazetidinone 12a reacted with isocyanates to give a range of ureas 14 (Scheme 
5). 
 
N
N
Boc
O Ph
O
RO
N
N
Boc
Ph
O
HO
7 (65%)
R = Me; various
conditions
R = Bn. H2 (1 atm),
10 % Pd/C (10% w/w)
MeOH, rt, 0.5 h4a  R = Me4c  R = Bn
N
N
Boc
Ph
O
N
H
8 (21%)
CDMT (1.1 eq)
NMM
MeCN, rt, 1.5 h
O
O
Ph
9 
 
Scheme 4. [Fur = 2-furyl] Synthesis of 1,2-diazetidinone-4-carboxamides.  
 
 
  
13a 13b 13d 
Figure 4. X-Ray crystal structures of 1,2-diazetidin-3-ones 13a, 13b and 13d (CCDC 
1829700, 1829701, 1829703 respectively). 
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Scheme 5. Synthesis of 1,2-diazetidin-3-one ureas.  
 
With a range of novel 1,2-diazetidin-3-ones in hand, it remained to carry out preliminary 
biological evaluation. The compounds were tested against a range of bacterial and fungal 
strains as part of the CO-ADD (Australia) antimicrobial screen, but for the most part were 
inactive. Compounds 13e and 14b showed activity antifungal activity against Cryptococcus 
neoformans var. grubii showing 91% and 51% inhibition of growth respectively after 2 h 
incubation. Further structure-activity relationship studies are ongoing. 
 
The compounds were also screened against two cancer cell lines: MCF-7 (mammary 
carcinoma) and HCT116 (colon carcinoma), using the MTT assay. The results are 
summarized in Table 1, and show that the compounds were largely inactive against colon 
carcinoma cells, but showed modest growth inhibitory activity in mammary carcinoma cells.  
 
Table 1. Growth inhibitory activity of 1,2-diazetidin-3-ones in MCF-7 and HCT-116 carcinoma 
cells lines. 
 
Compound 
GI50 mean ± SEM (μM) 
MCF-7 HCT-116 
5a 72.7 ± 12.3 >100 
5b 76.0 ± 7.51 >100 
6a 82.0 ± 18.0 >100 
N
NH
O Ph
O
N
12a 14a  R = c-C5H9 (72%)
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R
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6b 95.3 ± 6.69 >100 
12b 54.3 ± 4.18 >100 
13a 64.0 ± 3.51 >100 
13b 67.3 ± 6.06 >100 
13c 26.3 ± 21.9 41.3 ± 23.9 
13d 49.3 ± 10.7 >100 
13e 52.3 ± 2.60 >100 
13f 66.3 ± 12.9 >100 
14c 57.3 ± 9.70 >100 
MCF-7 breast cancer cells; HCT-116 colon cancer cells; cells were exposed to experimental 
agents for 48 h before viability was assessed by MTT assay. Mean ± SEM (standard error of 
the mean) of ≥3 independent trials are shown; n=4 per concentration per trial. 
 
Conclusion 
A range of 1,2-diazetidine-3-ones has been synthesized using intramolecular N–H insertion 
of a rhodium carbenoid as a key step. Although some attempts at subsequent derivatization 
could be thwarted by the lability of the 4-membered ring, a range of derivatives was 
accessed by functionalization of the pendant carboxylate group prior to cyclization. The 
compounds show modest biological activity. 
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Experimental Section 
Full experimental details are given in the Supporting Information, together with copies of 
NMR spectra. 
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